Healthy Q2; profitability guidance upgraded
01/08/24 -"Q2 profitability was above the street’s expectations. A decent performance across most of the segments was offset by a weaker showing from Genomics/NGS. While the 2024 sales guidance was impacted by ..."
Pages
61
Language
English
Published on
01/08/24
You may also be interested by these reports :
07/01/26
Yesterday, Meta announced a delay in the international rollout of the Ray-Ban display smart glasses. The market reacted positively to this news, on ...
30/12/25
Despite revising our estimates and target price downward, DiaSorin remains a compelling investment opportunity. This is underpinned by strong ...
15/12/25
We have revised our estimates upwards to account for enhanced profitability, despite the effects of tariffs and foreign exchange headwinds. This ...
11/12/25
CZM reported its full-year FY2024-25 results, aligning with guidance. Sales growth was supported by contributions from both segments, though ...